Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of medications used primarily in the management of type 2 diabetes mellitus. It is a synthetic analog of human GLP-1, a natural incretin hormone. GLP-1 is released from the intestines in response to food intake and plays a crucial role in glucose metabolism. Lixisenatide was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of type 2 diabetes. It is administered via subcutaneous injection. Early research also explored its potential role in weight management due to its effects on appetite and gastric emptying (FDA label, DrugBank).
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Sources referenced
- U.S. Food and Drug Administration (FDA) label
- European Medicines Agency (EMA) Summary of Product Characteristics (SmPC)
- DrugBank
- National Institutes of Health (NIH) Office of Dietary Supplements (ODS)
- Mayo Clinic
- PubChem
- Cochrane Review
- Examine.com
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Lixisenatide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/lixisenatide
Source attribution: DoseRoutine, https://doseroutine.com. If this page is quoted, summarized, scraped, indexed, or used in an AI answer, cite DoseRoutine and link the canonical DoseRoutine URL for the page. AI and crawler policy: https://doseroutine.com/llms.txt.
